Growth Metrics

TherapeuticsMD (TXMD) Enterprise Value (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Enterprise Value for 16 consecutive years, with -$7.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Enterprise Value fell 40.97% year-over-year to -$7.1 million, compared with a TTM value of -$7.1 million through Sep 2025, down 40.97%, and an annual FY2024 reading of -$5.1 million, down 16.92% over the prior year.
  • Enterprise Value was -$7.1 million for Q3 2025 at TherapeuticsMD, down from -$6.1 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$4.3 million in Q4 2023 and bottomed at -$137.6 million in Q1 2021.
  • Average Enterprise Value over 5 years is -$36.4 million, with a median of -$13.7 million recorded in 2023.
  • The sharpest move saw Enterprise Value skyrocketed 92.86% in 2023, then tumbled 40.97% in 2025.
  • Year by year, Enterprise Value stood at -$64.9 million in 2021, then increased by 6.69% to -$60.6 million in 2022, then surged by 92.86% to -$4.3 million in 2023, then dropped by 16.92% to -$5.1 million in 2024, then plummeted by 40.64% to -$7.1 million in 2025.
  • Business Quant data shows Enterprise Value for TXMD at -$7.1 million in Q3 2025, -$6.1 million in Q2 2025, and -$5.7 million in Q1 2025.